PALO ALTO, CA--(Marketwired - Mar 10, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the IMPACT-PCP (Investigation ...

Please provide your email address to receive an email when new articles are posted on . CAD was significantly prognostic of all-cause mortality in patients with heart failure. Mortality risk was ...

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced online publication of a study in the The paper, titled “A Gender Specific Blood-Based Gene Expression ...

Patients With Low Corus CAD Test Scores Had an 82% Decreased Odds for Further, Potentially Unnecessary Referral for Further Cardiac Evaluation CardioDx, Inc., a molecular diagnostics company ...

WASHINGTON, DC—Coronary CT angiography (CCTA) seems to have the edge over functional testing for the assessment of suspected CAD in patients with newly diagnosed type 2 diabetes, real-world data show.

Please provide your email address to receive an email when new articles are posted on . A low score on a blood test that evaluates age, sex and gene expression may help to rule out the presence of ...

The true incidence of obstructive coronary artery disease (CAD) among patients undergoing transcatheter aortic valve implantation (TAVI) is not known Assessment of CAD using angiography only can ...

CardioDx Also Separately Raises $20 Million in New Financing to Support the Company's Commercial Growth and Operations CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular ...

LONDON, UK — Taking a few extra minutes to perform carotid-artery ultrasound alongside stress echocardiography in patients with suspected coronary artery disease (CAD) offers incremental prognostic ...